Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker MNPR
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 600 | $72.21 | $43.3K Sale | Form 4 ↗ |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 996 | $71.35 | $71.1K Sale | Form 4 ↗ |
| Nov 4, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 1,295 | $70.75 | $91.6K Sale | Form 4 ↗ |
| Nov 2, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 1,502 | $70.04 | $105.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 200 | $68.68 | $13.7K Sale | Form 4 ↗ |
| Nov 2, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 600 | $67.06 | $40.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 840 | $66.16 | $55.6K Sale | Form 4 ↗ |
| Nov 2, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 1,199 | $70.10 | $84.0K Sale | Form 4 ↗ |
| Sep 24, 2026 | Chandler Robinson Chief Executive Officer, Director | MNPR Monopar Therapeutics Inc. | Sale | 600 | $89.79 | $53.9K Sale | Form 4 ↗ |
| Sep 24, 2026 | Chandler Robinson Chief Executive Officer, Director | MNPR Monopar Therapeutics Inc. | Sale | 8,368 | $88.97 | $744.5K Sale | Form 4 ↗ |
| Sep 24, 2026 | Chandler Robinson Chief Executive Officer, Director | MNPR Monopar Therapeutics Inc. | Sale | 9,638 | $87.96 | $847.8K Sale | Form 4 ↗ |
| Sep 24, 2026 | Chandler Robinson Chief Executive Officer, Director | MNPR Monopar Therapeutics Inc. | Sale | 10,450 | $87.15 | $910.7K Sale | Form 4 ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 590 | $113.84 | $67.2K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 602 | $112.93 | $68.0K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 1,098 | $111.84 | $122.8K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 700 | $110.65 | $77.5K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 615 | $109.56 | $67.4K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 485 | $108.83 | $52.8K Sale | Form 4/A ↗ |
| Aug 26, 2026 | Patrice Rioux | MNPR Monopar Therapeutics Inc. | Sale | 1 | $111.26 | $111 Sale | Form 4 ↗ |
| Aug 25, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 1,802 | $113.05 | $203.7K Sale | Form 4/A ↗ |
| Aug 25, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 646 | $111.07 | $71.8K Sale | Form 4/A ↗ |
| Aug 25, 2026 | Raymond Anderson Director | MNPR Monopar Therapeutics Inc. | Sale | 694 | $110.04 | $76.4K Sale | Form 4/A ↗ |
| Dec 26, 2025 | Quan Anh Vu Chief Financial Officer | MNPR Monopar Therapeutics Inc. | Buy | 1,500 | $69.95 | $104.9K Buy | Form 4 ↗ |
| Dec 18, 2025 | Arthur J. Klausner Director | MNPR Monopar Therapeutics Inc. | Sale | 461 | $68.09 | $31.4K Sale | Form 4 ↗ |
| Dec 18, 2025 | Arthur J. Klausner Director | MNPR Monopar Therapeutics Inc. | Sale | 4,660 | $67.06 | $312.5K Sale | Form 4 ↗ |
| Sep 24, 2025 | Tactic Pharma LLC Chief Executive Officer, Director, 10%… | MNPR Monopar Therapeutics Inc. | Sale | 550,229 | $63.61 | $35.0M Sale | Form 4 ↗ |
| Jul 14, 2025 | Kim R. Tsuchimoto Director | MNPR Monopar Therapeutics Inc. | Sale | 8,904 | $40.00 | $356.2K Sale | Form 4 ↗ |
| Jul 14, 2025 | Christopher M. Starr Director | MNPR Monopar Therapeutics Inc. | Sale | 16,800 | $40.00 | $672.0K Sale | Form 4 ↗ |
| Jul 14, 2025 | Chandler Robinson Chief Executive Officer, Director | MNPR Monopar Therapeutics Inc. | Sale | 16,800 | $40.00 | $672.0K Sale | Form 4 ↗ |
| Apr 2, 2025 | Michael J. Brown | MNPR Monopar Therapeutics Inc. | Sale | 33,334 | $35.00 | $1.2M Sale | Form 4 ↗ |
| Oct 28, 2024 | Karthik Radhakrishnan Chief Financial Officer | MNPR Monopar Therapeutics Inc. | Buy | 1,550 | $16.25 | $25.2K Buy | Form 4 ↗ |
31 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:39 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances